title: Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion.
abstract: OBJECTIVE
  To test the efficacy of an intravitreal dexamethasone implant in patients with recalcitrant macular edema secondary to retinal vein occlusion.
  
  
  METHODS
  A retrospective chart review was performed for 18 patients with retinal vein occlusion who received multiple bevacizumab intravitreal injections before treatment with an intravitreal dexamethasone implant.
  
  
  RESULTS
  Two subgroups of bevacizumab-resistant patients were identified. Both subgroups responded to subsequent treatment with an intravitreal dexamethasone implant with an average reduction in central foveal thickness of 146.8 ± 33.65 μm. A visual acuity improvement of 0.26 ± 0.07 (logarithm of minimal angle of resolution) was also noted. Intraocular pressure increased by an average of 3.33 ± 0.66 mmHg and was managed by 1.0 ± 0.5 topical drops.
  
  
  CONCLUSIONS
  A subset of patients do not have resolution of macular edema after treatment with intravitreal bevacizumab. Such patients may respond to treatment with an intravitreal dexamethasone implant.
authors.affiliation: Retina Macula Institute, Torrance, California 90503, USA.
authors.forename: Behnam
authors.initials: B
authors.lastname: Sharareh
authors.forename: Ron
authors.initials: R
authors.lastname: Gallemore
authors.forename: Mehran
authors.initials: M
authors.lastname: Taban
authors.forename: Spencer
authors.initials: S
authors.lastname: Onishi
authors.forename: Josh
authors.initials: J
authors.lastname: Wallsh
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D017211:Treatment Failure; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D004343:Drug Implants; D000068258:Bevacizumab; D003907:Dexamethasone